{
  "docId": "019de071-dcb4-71ce-82aa-3fde96763369",
  "docSlug": "c85401f3daf1ffc5cb0e20a3335252d7",
  "documentTitle": "BenevolentAI | SPAC Presentation Deck | 42 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 42,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a breakdown of disease severity percentages and a specific drug candidate profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-dcb4-71ce-82aa-3fde96763369/25",
  "deckHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369",
  "deckJsonHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369.json",
  "deckAnchorHref": "/decks/019de071-dcb4-71ce-82aa-3fde96763369#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.43,
        "x": 0.53,
        "y": 0.13
      },
      "kind": "callout",
      "text": "BEN-8744: Best-in-class, oral, peripherally restricted potent and selective drug for the treatment of Moderate-Severe Ulcerative Colitis",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0313091c-8280-4be6-8f41-7b02a4ef265d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "diagram",
      "text": "Ulcerative Colitis breakdown: 64% Mild-moderate, 31% Moderate-severe, 5% Severe-fulminant",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ec65144-75d3-4c62-99bd-a76f67f4a221",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "A chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum. Efficacy - 20-40% of Moderate-severe patients do not respond to anti-TNF. Safety - Treatments have many side effects. High unmet need.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b746c4a2-8760-4023-8544-fdce0996db41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.43,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "list",
      "text": "Phosphodiesterase 10 (PDE10) identified by TargetID. Molecular Design expertise. Expected efficacy. Targets Moderate and Severe UC/IBD patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec466e35-922f-450e-ac62-b29588966dde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Affects 0.4% US population(1), 1.7 million patients in 7MM(2), forecast $7.8bn market by 2026(3)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dbb3bba-dab8-455c-9178-27bcac00a82f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source (1) and (2):GlobalData: Ulcerative Colitis, Global Drug Forecast and Market Analysis to 2026; (3)Evaluate Pharma: Gastro-intestinal, Inflammatory bowel disease (IBD), Ulcerative colitis, Worldwide Overview (report 17th Sep 2021)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaccab5f-09cd-451f-b936-731e45e95f20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Ulcerative Colitis (UC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef839631-9b6e-4cef-9caf-d85a36e9e1c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}